epidemiology, 2039

etiology of, 2039

pathophysiology of, 2039

staging of, 2040t

treatment of, 2039–2040, 2040t

Lynch syndrome, 2085

M

MAC (see Mycobacterium avium complex (MAC))

Macronutrients, 747

carbohydrates, 747

lipids, 747–748

protein, 747

Macrosomia, 979, 989

Macrovascular disease

and glycemic control, 1078–1079, 1078–1079t

Macular degeneration, age-related, 1168–1169

Maculopapular acne, 827t, 828–830

Maculopapular eruptions, 823

Maculopapular rash, 972

MADRS (see Montgomery Asberg Depression Rating Scale (MADRS))

Magnesium, 27

blood chemistry reference values for, 18t

disorders of, 594–596

homeostasis, 593

Magnetic resonance imaging (MRI), 191

Maintenance fluids, 754–755

Major depressive disorder

diagnosis of, 1818

suicide assessment, 1824

Major histocompatibility complex (MHC), 717–718

Malaria

acute

signs of, 1695–1696

symptoms of, 1695–1696

treatment, 1696

antimalarial drugs, 1697t–1699t

characteristic paroxysms of, 1695

distribution, 1694

drug-resistant, 1695

epidemiology of, 1694

erythrocyte cycle of merozoites, 1694–1695

and G6PD deficiency, 1696

hemoprophylaxis against, 1701

mosquito protection measures, 1700t

non-falciparum prophylaxis, 1701

Plasmodium falciparum infections, 1695

prevention, 1696, 1699

prophylaxis for Plasmodium falciparum, 1701

sporozoites, 1695

standby emergency treatment, 1699–1701

transmission, 1694–1695

vaccination, 1701

Male libido, 2259

Malignancy, 1043

Malignancy-related anemia, 1943–1944

Malignant melanoma, UVR exposure and, 848

Malnutrition, 659, 749, 791

classification of, 751

Mania, in BD, 1839–1846

Manic-depression (see Bipolar disorder (BD))

Mantoux method (see Tuberculin skin test (Mantoux method))

MAO (see Maximal acid output (MAO))

Maple syrup urine disease, 2145–2146

MAP (see Mean arterial pressure (MAP); Medication action plan (MAP))

MAR (see Medication administration record (MAR))

MARISA (see Monotherapy Assessment of Ranolazine in Stable Angina (MARISA))

MASCC (see Multinational Association of Supportive Care in Cancer (MASCC))

Maternal iron deficiency, 968

Maternal tachycardia, 996

Matrix metalloproteinases (MMP), 867

Matthew–Rumack nomogram, 79

Maturity-onset diabetes of the young (MODY), 1075

Maximal acid output (MAO), 492

MBSR (see Mindfulness-based stress reduction (MBSR))

McGill Pain Questionnaire, 1174, 1175t, 1184

MCH (see Mean cell hemoglobin (MCH))

MCHC (see Mean cell Hgb concentration (MCHC))

MCTs (see Medium-chain triglycerides (MCTs))

MCV (see Mean cell volume (MCV))

MDCT (see Multi-detector CT (MDCT))

MDI (see Metered-dose inhaler (MDI))

MDRD (see Modification of Diet in Renal Disease (MDRD))

Mean arterial pressure (MAP), 133, 351

normal values of, 350t

Mean cell hemoglobin (MCH), 33

Mean cell Hgb concentration (MCHC), 31

Mean cell volume (MCV), 32–33

Measles, mumps, rubella (MMR), 1353

Mechanical ventilation, 46

Meconium aspiration, 989

Meconium ileus equivalent (see Distal intestinal obstruction syndrome (DIOS))

Medical history, 1–4

Medical nutrition therapy (MNT), 1076, 1080–1081

physical activity, 1081

principles of, 1080

specific components, 1080–1081

for type 1 diabetes, 1080

for type 2 diabetes, 1080

Medical Therapy of Prostate Symptoms (MTOPS), 2258

Medicare, EN and, 788, 789t

Medicare Hospice Benefit, 84–85, 84t

Medicare Prescription Drug Improvement and Modernization Act of 2003, 2217

Medication action plan (MAP), 5, 10, 12f, 13

Medication administration record (MAR), 3

Medication errors, 5

Medication history, 5–6

Medication overuse, definition of, 1243

Medication reconciliation, 2

Medication therapy management

in

a

c

ut

e

c

a

r

e

s

e

tt

in

g

,

1

3

–

1

4

a

n

d

a

s

s

e

s

s

me

nt

o

f

th

e

r

a

p

y

,

1

–

2

,

2

f

c

o

mmunity

p

h

a

r

ma

c

y/

a

mb

ula

t

o

r

y

s

e

tt

in

g

do

c

ume

nt

a

t

io

n

a

n

d

fo

llo

w

-

up

,

1

0–

1

3

int

e

r

v

e

nt

io

n

a

n

d

r

e

fe

r

r

a

l,

1

0

me

dic

a

t

io

n

a

c

t

io

n

p

la

n

(

M

A

P

)

,

1

0

,

1

2

f

me

dic

a

t

io

n

th

e

r

a

p

y

r

e

v

ie

w

(

M

T

R

)

,

9

,

9

t

p

e

r

s

o

n

a

liz

e

d

me

dic

a

t

io

n

r

e

c

o

r

d

(

P

M

R

)

,

1

0

,

1

0

f

e

ffe

c

t

iv

e

c

o

mmunic

a

t

io

n

,

a

n

d

p

a

t

ie

nt

int

e

r

v

ie

w

,

3

–

4

,

4

t

p

a

t

ie

nt

h

is

t

o

r

y

,

o

b

t

a

inin

g

a

,

4

me

dic

a

l

h

is

t

o

r

y

,

4

me

dic

a

t

io

n

h

is

t

o

r

y

,

5

–

6

s

o

c

ia

l

h

is

t

o

r

y

,

6

p

a

t

ie

nt

in

fo

r

ma

t

io

n

,

s

o

ur

c

e

s

o

f,

2

,

3

t

p. 2

3

5

1

p. 2

3

5

2

d

a

t

a

-

p

o

o

r

e

nv

ir

o

nme

nt

,

3

d

a

t

a

-

r

ic

h

e

nv

ir

o

nme

nt

,

3

p

a

t

ie

nt

th

e

r

a

p

y

,

a

pp

r

o

a

c

h

t

o

,

a

s

s

e

s

s

me

nt

o

f,

6–

7

,

6

t

a

s

s

e

s

s

me

nt

,

8

–

9

o

bj

e

c

t

iv

e

d

a

t

a

,

8

p

a

t

ie

nt

e

du

c

a

t

io

n

,

9

p

la

n

,

9

p

r

o

b

le

m

lis

t

,

7

–

8

,

7

t

s

ubj

e

c

t

iv

e

d

a

t

a

,

8

p

h

a

r

ma

c

o

g

e

n

o

mic

s

,

1

4

M

e

d

i

c

a

t

i

o

n

t

h

e

r

a

p

y

m

a

n

a

g

e

m

e

n

t

s

e

rv

i

c

e

s

(

M

T

M

S

)

,

1

–

1

4

M

e

d

i

c

a

t

i

o

n

t

h

e

r

a

p

y

r

e

v

i

e

w

(

M

T

R

)

,

9

,

9

t

M

e

d

i

t

a

t

i

o

n

,

1

1

9

7

t

M

e

d

i

t

e

r

r

a

n

e

a

n

d

i

e

t

,

1

1

4

2

M

e

d

i

u

m

-

c

h

a

i

n

t

ri

g

l

y

c

e

ri

d

e

s

(

M

C

T

s

)

,

7

9

3

M

E

D

(

s

e

e

M

i

n

i

m

a

l

e

ryt

h

e

m

a

l

d

o

s

e

(

M

E

D

)

,

o

f

U

V

r

a

d

i

a

t

i

o

n

)

M

e

g

a

l

o

b

l

a

s

t

i

c

a

n

e

m

i

a

,

1

9

3

3

–

1

9

3

8

M

e

l

a

n

c

h

o

l

i

a

,

1

8

1

4

M

e

l

a

n

o

m

a

,

U

VR

e

x

p

o

s

u

r

e

a

n

d

,

8

4

6

M

E

L

D

(

s

e

e

M

o

d

e

l

fo

r

E

n

d

-

S

t

a

g

e

L

i

v

e

r

D

i

s

e

a

s

e

(

M

E

L

D

)

)

M

e

n

i

n

g

e

s

,

1

3

6

7

M

e

n

i

n

g

i

t

i

s

,

1

3

2

4

t

,

1

3

6

8

–

1

3

8

0

a

s

e

p

t

ic

,

1

3

6

8

c

e

r

e

b

r

o

s

p

in

a

l

fluid

fin

din

g

s

in

,

1

3

7

0

,

1

3

7

0

t

c

linic

a

l

fe

a

tur

e

s

o

f,

1

3

6

9

–

1

3

7

0

,

1

3

6

9

t

E

nt

e

r

o

b

a

c

t

e

r

,

1

3

7

8

gr

a

m

-

n

e

g

a

t

iv

e

b

a

c

illa

r

y

,

1

3

7

7

–

1

3

7

8

H

a

e

mop

h

ilu

s

in

flu

e

nz

a

e

–

in

du

c

e

d

,

1

3

6

8

mic

r

o

b

io

lo

gy

o

f,

1

3

6

8

,

1

3

6

8

t

,

1

3

7

0

N

e

is

s

e

r

ia

me

nin

g

it

idis

,

1

3

7

4–

1

3

7

6

in

n

e

o

n

a

t

e

s

,

1

3

2

3

,

1

3

6

8

p

a

th

o

g

e

n

e

s

is

a

n

d

p

a

th

op

hy

s

io

lo

gy

o

f,

1

3

6

8

–

1

3

6

9

p

e

nic

illin

-

s

u

s

c

e

p

t

ib

le

p

n

e

umo

c

o

c

c

a

l,

1

3

7

7

S

tr

e

p

t

o

c

o

c

c

u

s

p

n

e

umo

nia

e

,

1

3

7

6–

1

3

7

7

tr

e

a

tme

nt

o

f,

1

3

7

0–

1

3

8

0

M

e

n

i

n

g

o

c

o

c

c

a

l

d

i

s

e

a

s

e

,

1

3

5

9